Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

SGLT2 inhibitors may prevent diabetes

Nature Reviews Nephrology volume 18, pages 203–204 (2022)Cite this article

Subjects

Dapagliflozin reduces the risk of new-onset diabetes mellitus, according to results from a pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials. The study adds to the growing list of sodium–glucose co-transporter 2 inhibitor benefits and raises the possibility of an expanded target patient population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Effect of SGLT2 inhibitors on the risk of a new-onset diagnosis of diabetes in people with prediabetes.

References

  1. Nomura, S. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355–6360 (2010).

    Article  CAS  Google Scholar 

  2. Herrington, W. G. et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Fail. 23, 1260–1275 (2021).

    Article  CAS  Google Scholar 

  3. Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022).

    Article  CAS  Google Scholar 

  4. Inzucchi, S. E. et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care 44, 586–594 (2021).

    Article  CAS  Google Scholar 

  5. Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370–385 (2017).

    Article  CAS  Google Scholar 

  6. Folz, R. & Laiteerapong, N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 64, 2131–2137 (2021).

    Article  Google Scholar 

  7. Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).

    Article  CAS  Google Scholar 

  8. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).

    Article  CAS  Google Scholar 

  9. International Diabetes Federation. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021); https://www.diabetesatlas.org

  10. Cai, X. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Br. Med. J. 370, m2297 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

D.V.O. receives support through an Australian Government Research Training Program Scholarship and an NHMRC Clinical Trials Centre Postgraduate Research Scholarship. M.J.J. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship.

Author information

Authors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia

    Daniel V. O’Hara & Meg J. Jardine

  2. Royal North Shore Hospital, Sydney, New South Wales, Australia

    Daniel V. O’Hara

  3. Concord Repatriation General Hospital, Sydney, New South Wales, Australia

    Meg J. Jardine

Authors
  1. Daniel V. O’Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meg J. Jardine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meg J. Jardine.

Ethics declarations

Competing interests

M.J.J. is responsible for research projects that have received funding from CSL, Dimerix, Eli Lilly and MSD and has received advisory, steering committee and/or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL, Janssen, Merck, MSD, Roche and Vifor (all consultancy fees or honoraria are paid to her institution). D.V.O. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Hara, D.V., Jardine, M.J. SGLT2 inhibitors may prevent diabetes. Nat Rev Nephrol 18, 203–204 (2022). https://doi.org/10.1038/s41581-022-00541-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-022-00541-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing